RJA
HGEN

Raymond James & Associates’s HUMANIGEN, INC. HGEN Stock Holding History

Raymond James & Associates’s Portfolio HGEN Stock Details HGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,300
Closed -$1.48K – 4016
2023
Q1 		$1.48K Buy
+10,300
New +$1.65K ﹤0.01% 3867
2021
Q4 		– Sell
-10,160
Closed -$60K – 4319
2021
Q3 		$60K Buy
+10,160
New +$143K ﹤0.01% 3898

Other funds holding HGEN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James & Associates's HGEN Position: Q2 2023 in Review

Raymond James & Associates sold out of HUMANIGEN, INC. (HGEN) in Q2 2023, closing a stake of 10,300 shares — an estimated $1.48K sold.

Raymond James & Associates first reported a position in HGEN in Q3 2021 and held it in 2 quarters. The position peaked at $60K in Q3 2021. 38 funds tracked by Wall St. Rank hold HGEN as of Q2 2023.

  • Raymond James & Associates reported no remaining HUMANIGEN, INC. position as of Q2 2023 after selling out during the quarter.
  • Raymond James & Associates sold 10,300 HUMANIGEN, INC. shares in Q2 2023, an estimated $1.48K.
  • Raymond James & Associates first reported a position in HUMANIGEN, INC. in Q3 2021 and held it in 2 quarters.
  • Raymond James & Associates's HUMANIGEN, INC. position peaked at $60K in Q3 2021.
  • 38 funds tracked by Wall St. Rank held HUMANIGEN, INC. as of Q2 2023.

Based on Raymond James & Associates's 13F filing for Q2 2023, filed 25 Jul 2023.